Malik Shahzad 4
4 · Acutus Medical, Inc. · Filed Aug 12, 2020
Insider Transaction Report
Form 4
Malik Shahzad
Director
Transactions
- Conversion
Common Stock
2020-08-10+1,551,713→ 1,551,713 total(indirect: See footnote) - Conversion
Common Stock
2020-08-10+65,436→ 65,436 total(indirect: See footnote) - Conversion
Series A Convertible Preferred Stock
2020-08-10−10,738→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (10,738 underlying) - Conversion
Series B Convertible Preferred Stock
2020-08-10−34,261→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (34,261 underlying) - Conversion
Series C Convertible Preferred Stock
2020-08-10−13,195→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (13,195 underlying) - Conversion
Series C Convertible Preferred Stock
2020-08-10−312,840→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (312,840 underlying) - Conversion
Series D Convertible Preferred Stock
2020-08-10−171,695→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (171,695 underlying) - Conversion
Series A Convertible Preferred Stock
2020-08-10−254,495→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (254,495 underlying) - Conversion
Series B Convertible Preferred Stock
2020-08-10−812,683→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (812,683 underlying) - Conversion
Series D Convertible Preferred Stock
2020-08-10−7,242→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (7,242 underlying)
Holdings
- 2,222
Common Stock
Footnotes (3)
- [F1]These shares are held by Advent Life Sciences LLP ("Advent"). The Reporting Person is a general partner of Advent, and disclaims beneficial ownership of the securities held by Advent except to the extent of his indirect pecuniary interest therein.
- [F2]These shares are held by Advent Life Sciences Fund I LP. Advent is the general partner of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent. The Reporting Person disclaims beneficial ownership of the securities held by Advent Life Sciences Fund II LP except to the extent of his indirect pecuniary interest therein.
- [F3]Each of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date.